Parameter | Value (95% CI) | Distribution | Data source | Method | ||
---|---|---|---|---|---|---|
 | Total population | Ineligible population | Eligible population |  |  |  |
Birth cohort (%) | 182,662 | 168,215 (92.1%) | 14,448 (7.9%) | - | Statistics Netherlands [46], Dutch Perinatal Registry [38], Eurocat [37] | Published results on birth cohort size and prevalence of high risk conditions |
RV incidence | Â | Â | Â | Â | Â | Â |
<1 year | 18,075 (11,768; 22,932) | Calculated | Calculated | Pert | Community-based cohort study [47] | Incidence based on simulations from original study data updated to 2011 population size, see Mangen et al. for details [45] Distribution among eligible and ineligible based on relative size of each group in birth cohort |
1 to 4 years | 42,218 (24,711; 56,272) | Â | Â | Â | Â | Â |
5 to 64 years | 147,997 (41,573;282,866) | Â | Â | Â | Â | Â |
5 to 9 years | 6.2% of 5 to 64 years | Â | Â | Â | Â | Based on age-distribution of cases 5 to 64 years in original study data |
10 to 14 years | 2.9% of 5–64 years |  |  |  |  | |
GP visits 0 to 1 years | 21.2% (12.8; 26.5) | Calculated | Calculated | Pert | GP based cohort study [48] | Percentage of all RV cases, based on simulations from original GP study data, see Mangen et al. for details [45]. Distribution among eligible and ineligible based on relative size of each group in birth cohort |
GP visits 1 to 4 years | 18.7% (16.4; 19.9) | Â | Â | Â | Â | Â |
GP visits 5 to 14 years | 4.0% (1.8; 4.7) | Â | Â | Â | Â | Â |
Hospitalization (95% CI) | Calculated | 3,884 (3,244; 4,524) | 491 (357; 626) | Pert | RoHo-study | Weighted incidence estimation based on original study data, see Bruijning-Verhagen et al. for details [33]. |
Nosocomial (95% CI) | Calculated | 227 (162; 293) | 269 (172; 365) | Pert | RoHo-study | Weighted incidence estimation based on original study data, see Bruijning-Verhagen et al. for details [33] |
Mortality rate (per 1,000 RV hospitalizations) | Calculated | 0.00 (0.00; 0.04) | 0 81 (0.36; 1.46) | Triangular | RoHo study, External dataset Sophia Children’s hospital | Observed mortality cases from both sources were combined for weighted mortality rate estimation |
Age distribution of RV hospitalizations and fatal cases | Additional file 1: Table S2 | Â | RoHo study | Â | ||
Utilities RV gastroenteritis | QALY Loss | Â | Â | Â | ||
Mild (RV episode without medical care) | 0.0011/0.002a | Â | Published data | |||
Moderate (GP visit) | 0.0022/0.004a | Â | Â | Â | ||
Severe (Hospitalization) | 0.0022/0.004a | Â | Â | Â | ||
Nosocomial | Calculated | Calculated | Calculated | Â | RoHo Study | Based on severity distribution of nosocomial cases observed in RoHo-study |
Mortality | Calculated | 80.7 minus patient’s age | Simulated, whereby assuming a life expectancy of 1; 20; 41.3 minus patient’s age with probability of 1/3 eachb | Uniform | Statistics Netherlands [46], Expert opinion | For ineligible: Based on average life expectancy in the Netherlands. For eligible: Based on expert panel†|
Direct healthcare costs (Euro) | Â | Â | Â | Â | Â | Â |
Gastroenteritis episodes without medical care | 0 | Fixed | Â | Â | ||
Standard GP visits | 29 | Â | Guidelines for health-economic evaluations [39] | Standard Cost Prices. See Mangen et al. for details [45] | ||
 Home visit GP | 45 |  |  |  | ||
 GP consultation by phone | 15 |  |  |  | ||
 Prescriptions | 40 |  | Community-based cohort study and GP based cohort study [49, 50] | See Mangen et al. [45] | ||
Laboratory costs | 73 | Â | Â | Â | ||
Hospitalization | Calculated | 2,179 (2,027;2,330) | 2,550 (2,508; 3,606) | Pert | RoHo study | Weighted estimates from original study data, see Additional file 1 |
Nosocomial | Calculated | 1,995 (1,242; 2,748) | 2,129 (1,203; 3,055) | Â | Â | Â |
Direct non-healthcare costs | Â | Â | Â | Â | Â | Â |
RV episode without medical care | Additional diapers | Uniform | Assumption | See Mangen et al. [45] | ||
GP visits | Additional diapers and travel costs | Â | Guidelines for health-economic evaluations [39] | Â | ||
Hospitalization | Travel costs | Pert | Â | Â | ||
Nosocomial | Â | Â | Â | Â | Â | Â |
Indirect non-healthcare costs c | Â | Â | Â | Â | ||
Costs per hour work loss (euro) | 31.11 | Fixed | Statistics Netherlands [48] Guidelines for health-economic evaluations [39] | See Mangen et al. [45] | ||
Hours of work loss for RV episode without medical care | 0.93; 1.36; 0.84 for ages 0 to 4; 5 to 9 and 10 to 14 years respectively | Uniform | Community-based cohort study and GP based cohort study [49, 50] | Dependent of patient-age. See Mangen et al. [45] | ||
Hours of work loss GP visits | 1.35; 1.98; 1.23 for ages 0 to 4; 5 to 9 and 10 to 14 years respectively | Uniform | Â | Â | ||
Hours of work loss Hospitalization | 37.32 | Â | hospital based observational study [51] | Based on the findings from Friesema et al. [52] for children up to 18, Further details see Mangen et al. [45] | ||
Hours of work loss Nosocomial | 24.58 | Â | Â | Based on the findings from Friesema et al. [52] for children up to 18, adjusted for excess duration of hospitalization among nosocomial in RoHo study (2.7 versus 2.9 days) | ||
Vaccine efficacy | Table 2 |  |  | |||
Herd-immunity | Universal RV vaccination | Targeted RV vaccination | Â | Â | Â | |
 | 30% (0% to 46%) | - |  | Triangular | Observational studies from US [58, 59], Australia [60, 61], Belgium [62] | Published data |
Vaccination costs | Â | Â | Â | Â | Â | Â |
 RV1 | 60; 75; 90 | 80; 100; 120 |  | Previous CEA [10] For Eligible: Assumption | Assumed tender Price | |
 RV5 | 60; 75; 90 | 80; 100; 120 |  |  |  | |
 Startup costs first year | 218,440 | - |  |  |  |  |
 Application costs | 6.44 |  |  | See Mangen et al. [45] | ||
 Administration costs | 1.64 |  |  |  |